Ignite Creation Date:
2025-12-24 @ 9:31 PM
Ignite Modification Date:
2026-01-04 @ 9:19 PM
Study NCT ID:
NCT00297232
Status:
TERMINATED
Last Update Posted:
2016-07-15
First Post:
2006-02-27
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Natalizumab (Tysabri) Re-Initiation of Dosing
Sponsor:
Biogen
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
101-MS-321
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None